Published July 1, 2023 | Version v1
Journal article Open

Analytical Method Development and Validation Method for The Estimation of Related Impurities in Combined Dosage Form of Atazanavir and Cobicistat By RP-HPLC

Authors/Creators

  • 1. Research Scholar & 2Associate Professor, Bhupal Nobles College of Pharmacy, Udaipur, Rajasthan - 313001.

Contributors

  • 1. associate Professor, Bhupal Nobles College of Pharmacy, Udaipur, Rajasthan - 313001.
  • 2. Associate Professor, Faculty of Pharmacy, Maulana Azad University, Jodhpur, Rajasthan - 342802.

Description

Abstract
A simple, economic, selective, and precise RP-HPLC method has been developed and validated for the estimation of related impurities of Atazanavir and Cobicistat in combined dosage form. Chromatographic separation has been achieved by using LC-20 AT C18 (250mm x 4.6mm, 5μm) column and using mobile phase buffer (potassium dihydrogen phosphate, pH 3.0): acetonitrile (60:40), 1mL/min was a flow rate. Samples were scanned at a wavelength of 224 nm. As per the ICH guidelines the method is validated. Retention time of Cobicistat and Atazanavir were found to be 5.247 and 3.513 respectively and the retention time of Atazanavir impurity and Cobicistat impurity were found to be 2.747 minute and 4.370 minute respectively. Validation of the method was successfully established by performing various validation parameters such as specificity, precision, linearity, accuracy, LOD, LOQ, robustness, ruggedness according to ICH guidelines. The linearity was observed in the range of 2.5-7.5 μg/mL for related impurities of Atazanavir and 2.5-7.5 μg/mL for related impurities of Cobicistat. The LOD value was found 0.206 μg/mL and 0.342 μg/mL for Atazanavir impurity and Cobicistat impurity respectively. The proposed method was found to be specific, linear, sensitive, precise, accurate and robust in nature.
Keywords
Atazanavir, Cobicistat, related impurities RP-HPLC Method, Validation.

Files

179-190-Analytical-Vimla Soni-1199048125.pdf

Files (617.5 kB)

Name Size Download all
md5:5520b872fe0980d1e3b6ac43403a1ba6
617.5 kB Preview Download

Additional details

Dates

Available
2023-07-01
Volume 13 issue 3 2023

References

  • [1] Moore R D., Chaisson R.E. Natural history of HIV infection in the era of combination Antiretroviral therapy. Natural history of HIV, 13(14):1933-1942, (1993). doi: 10.1097/00002030-199910010-00017. [2] Derbyshire J. Perspectives in drug therapy of HIV infection. Drug therapy of HIV infection, 38-40, (1995). [3] Srinivasu K, Rao J. V., Mukkanti K. A Validated RP-HPLC Method for the Determination of Atazanavir in Pharmaceutical Dosage Form. E.J. Chemistry, 8(1):453-456, (2011). [4] Rapeti D, Reddy G, Narayanarao K, Shyamala P, Krishna R. Related substance by HPLC method for the detection and evaluation of impurities in ezetimibe drug material. Int. J. Pharm. Sci., 12(1):217-225, (2021). [5] Fatima U., Mamathal T., Gajula R. A, A novel RP-HPLC method development and validation of Cobicistat in bulk drug and tablet dosage form. Der Pharm. Sinica, 5(5):99-105, (2014). [6] Madhavi S., Rani A. P., Development and Validation of Bioanalytical Method for the Determination of Cobicistat from Human Plasma. Asian J. Pharm. analysis, 6:216-226, (2016). [7] Madhuri P. L., Sankar D. G. Bio analytical method development and validation for simultaneous estimation of atazanavir and cobicistat by RP-HPLC in human plasma. World J. Pharm. Sci, 4:28-36, (2016). [8] Devilal J, Narottam P., Sumalatha K., Srinivasa R. A. New Method Development and Validation for Simultaneous Determination of Atazanavir and Cobicistat in Bulk and Tablet Dosage Form by UPLC. Der Pharmacia Lettre, 10:1-9, (2018). [9] Naazneen S., Sridevi A., Stability Indicating RP-HPLC Method For the Simultaneous Estimation of Atazanavir and Cobicistat in Bulk And Tablet Dosage Form. IOSR J. Pharma. Bio. Sci, 12:61-68, (2017). [10] Menaka T., Kuber R. Analytical method development and validation for related substances in dipyridamole by RP -HPLC. Int. J. Pharm. Sci., 11(4):1823-1830, (2020). [11] Desaraju B., Rao B., Gangarapu K., Thumma G., Bakshi V. Method development and validation for related impurities of efavirenz by RP-HPLC method. 7:737-747, (2017). [12] Pakalapati S., Rumalla C., Gudapati A., Korupolu R., Gajbhiy S., Kallyaperumal M. A novel RP-HPLC method development and validation for determination and estimation of eluxadoline drug with its impurities. SN applied sci., 2(6):1036, (2020). [13] Hasan N., Shyamala J., Sharma J. V. C., Vishnu P. Method Development and Validation of Atazanavir in Pharmaceutical Formulation by RP-HPLC Method. Int. J. Pharm. Sci., 5(1):4-7, (2015). [14] Rao K. P., Ramana G. V., Rao M. C. Development and Validation of New Stability Indicating RP-HPLC method for the Assay of Atazanavir in Pure and Dosage Forms. Der Pharm. Lett., 8(13):259-266, (2016). [15] ICH guideline validation of analytical procedures: Text and Methodology Q2(R1). In international conference on Harmonisation, Geneva, Switzerland, (1996).